Novartis Salutes Terrell Davis Migraine Foundation; NFL MVP, Terrell Davis to Receive 'TD' Donation

Jan 25, 1999, 00:00 ET from Novartis Pharmaceuticals Corporation

    MIAMI, Jan. 25 /PRNewswire/ -- When football season kicked off, Novartis
 Pharmaceuticals Corporation pledged a $1,000 donation to the Terrell Davis
 Migraine Foundation for each touchdown Terrell scored during the regular
 season.  As a result of Davis' MVP season, Novartis will present him with a
 check in the amount of $25,000 to the Foundation.
     Terrell Davis has suffered from migraine headaches since the age of seven.
 His debilitating condition gained national attention when a sudden migraine
 hit him during Super Bowl XXXII.  Davis was able to overcome his migraine and
 score the winning touchdown after being treated with DHE (dihydroergotamine
 mesylate) -- a product now available from Novartis as Migranal(R) Nasal
     The Terrell Davis Migraine Foundation, headquartered in Englewood,
 Colorado, was established to help raise national awareness about the impact of
 living with headaches, particularly migraine, and serves to educate sufferers
 and their families about treatment options.  The Foundation is funded by
 Terrell Davis, public donations and with the help of a start-up grant from
 Novartis Pharmaceuticals Corporation.
     Since its inception, the Terrell Davis Migraine Foundation efforts have
 included the production of a motivational video they will distribute to
 primary and secondary schools.  In addition, local youth migraine sufferers
 have been hosted at select Bronco football games for an opportunity to meet
 Terrell and learn about his experience with migraine headaches and the
 importance of seeking medical care.
     "We are very excited to support the NFL MVP with his migraine Foundation,"
 said Chris Tama, vice president, central nervous systems, Novartis
 Pharmaceuticals Corporation.  "We share a common goal with Terrell and want to
 help the Foundation accomplish its goal of educating and providing support for
 the over 20 million Americans who suffer from migraine headaches."
     "I am grateful to Novartis for their contribution and support of the
 Foundation," said Davis.  "I know first-hand the tremendous toll that migraine
 headaches take on a person's life.  I've learned that there are effective
 treatments that enable me to 'get back in the game.'  By providing the proper
 resources and education, the Foundation can help other sufferers improve their
 'game' of life."
     For more information about the Terrell Davis Foundation for migraine
 education, consumers can call 800-426-8786.
     Novartis is a world leader in Life Sciences with core business in
 Healthcare, Agribusiness and Nutrition.  In 1997, Novartis Group sales were
 31.2 billion Swiss francs (USD 21.6 billion), of which 18.8 billion
 (USD 13.0 billion) were in Healthcare, 8.3 billion (USD 5.8 billion) in
 Agribusiness and 4.1 billion (USD 2.8 billion) in Nutrition.  The group
 annually invests more than 3.6 billion Swiss francs (USD 2.5 billion) in R&D.
 Headquartered in Basel, Switzerland, Novartis employs about 86,000 people and
 operates in over 100 countries around the world.
     * Migranal Nasal Spray, indicated for the acute treatment of migraine
 headaches, was made available by prescription in pharmacies nationwide in
 January 1998.  In clinical trials, self-administration of Migranal Nasal Spray
 resulted in migraine pain relief and reduction in pain intensity.  Over
 50 percent of patients in pivotal clinical trials did not need additional
 medications during the 24-hour period following a single 2 mg Migranal
     In clinical trials, side effects were usually mild and transient.  The
 most common were rhinitis, altered sense of taste, nausea, vomiting, dizziness
 and application site reaction.
     Full prescribing information is available from Novartis Pharmaceuticals

SOURCE Novartis Pharmaceuticals Corporation